Compositions that treat or inhibit pathological conditions associated with inflammatory response
View Patent ↗A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
1. A method of treating inflammation associated pain in a mammal, the method comprising administering to the mammal a composition comprising a first component selected from the group consisting of dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, hexahydro-adhumulone and a second component selected from the group consisting of rosemary, an extract derived from rosemary, a compound derived from rosemary, oleanolic acid, and ursolic acid.
2. The method of claim 1 , wherein the first component dihydro-isohumulone, dihydro-isocohumulone, dihydro-adhumulone, tetrahydro-isohumulone, tetrahydro-isocohumulone, tetrahydro-adhumulone, hexahydro-isohumulone, hexahydro-isocohumulone, hexahydro-adhumulone is derived from hops.
3. The method of claim 1 , wherein the composition comprises about 0.5 to 10000 mg of the first component.
4. The method of claim 3 , wherein the composition comprises about 50 to 7500 mg of the first component.
5. The method of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the first component.
6. The method of claim 5 , wherein the composition comprises about 0.1 to 1 weight percent of the first component.
7. The method of claim 1 , wherein the second component is rosemary.
8. The method of claim 1 , wherein the second component is an extract derived from rosemary.
9. The method of claim 1 , wherein the composition further comprises a third component different from the second component, said third component is a triterpine species selected from the group consisting of oleanolic acid and ursolic acid.
10. The method of claim 1 , wherein the second component is a compound derived from rosemary that is selected from the group consisting of 1,8-cineole, 19-alpha-hydroxyursolic acid, 2-beta-hydroxyoleanolic acid, 3-O-acetyloleanolic acid, 3-O-acetylursolic acid, 6-methoxy-luteolin-7-glucoside, 6-methoxyluteolin, 6-methoxyluteolin-7-glucoside, methoxyluteolin-7-methylether, 7-ethoxy-rosmanol, 7-methoxy-rosmanol, alpha-amyrin, alpha-humulene, alpha-hydroxyhydrocaffeic acid, alpha-pinene, alpha-terpinene, alpha-terpinenyl acetate, alpha-terpineol, alpha-thujone, apigenin, apigenin-7-glucoside, curcumene, benzyl-alcohol, beta-amyrenone, beta-amyrin, beta-elemene, beta-pinene, betulin, betulinic acid, bomeol, bomyl-acetate, caffeic acid, camphene, camphor, camosic acid, carnosol, carvacrol, carvone, caryophyllene, caryophyllene-oxide, chlorogenic acid, diosmetin, gamma-terpinene, hesperidin, isoborneol, limonene, luteolin, luteolin-3′-O-(3″-O-acetyl)-beta-D-glucuronide, luteolin-3′-O-(4″-O-acetyl)-beta-D-glucuronide, luteolin-3′-O-beta-D-glucuronide, luteolin-7-glucoside, methyl- eugenol, myrcene, neo-chlorogenic acid, nepetin, octanoic acid, oleanolic acid, p-cymene, piperitenone, rosmanol, rosmaric acid, rosmaricine, rosmaridiphenol, rosemarinic acid, rosmarinol, rosmariquinone, sabinene, sabinyl acetate, salicylates, salicyclic acid-2-beta-D-glucoside, squalene, terpinen-4-ol, terpinolene, thymol, trans-anethole, trans-carveol, ursolic acid, verbenone, and zingiberene.
11. The method of claim 10 , wherein the second component is a compound derived from rosemary that is selected from the group consisting of betulin, betulinic acid, camosic acid, camosol, carvacrol, chlorogenic acid, diosmetin, limonene, and luteolin.
12. The method of claim 1 , wherein the composition comprises about 0.5 to 5000 mg of the second component, wherein the second component is selected from the group consisting of rosemary, extract derived from rosemary, and a compound derived from rosemary.
13. The method of claim 12 , wherein the composition comprises about 5 to 2000 mg of the second component, wherein the second component is selected from the group consisting of rosemary, extract derived from rosemary, and a compound derived from rosemary.
14. The method of claim 1 , wherein the composition comprises about 0.035 to 3500 mg of oleanolic acid or ursolic acid.
15. The method of claim 14 , wherein the composition comprises about 0.7 to 700 mg of oleanolic acid or ursolic acid.
16. The method of claim 1 , wherein the composition comprises about 0.001 to 10 weight percent of the second component.
17. The method of claim 1 , wherein the composition comprises about 0.1 to 1 weight percent of the second component.
18. The method of claim 1 , wherein a ratio of the first component to the second component is in the range of about 100:1 to about 1:100.
19. The method of claim 1 , wherein the ratio of the first component to the second component is in the range of about 50:1 to about 1:50.
20. The method of claim 1 , wherein the composition further comprises a pharmaceutically acceptable carrier.
21. The method of claim 1 , wherein the composition is administered orally, topically, parenterally, or rectally.
22. The method of claim 1 , wherein said composition comprises, oleanolic acid and an extract derived from rosemary.
23. The method of claims 1 , wherein the composition further comprises glucosamine.